Inovio Pharmaceuticals Inc (INO) Expected to Announce Earnings of -$0.29 Per Share

Equities analysts predict that Inovio Pharmaceuticals Inc (NASDAQ:INO) will report earnings of ($0.29) per share for the current quarter, according to Zacks. Two analysts have issued estimates for Inovio Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.24) and the lowest estimate coming in at ($0.33). Inovio Pharmaceuticals reported earnings per share of ($0.36) during the same quarter last year, which would suggest a positive year-over-year growth rate of 19.4%. The company is scheduled to report its next earnings results on Wednesday, March 21st.

According to Zacks, analysts expect that Inovio Pharmaceuticals will report full year earnings of ($1.12) per share for the current financial year, with EPS estimates ranging from ($1.18) to ($1.03). For the next year, analysts expect that the company will post earnings of ($1.26) per share, with EPS estimates ranging from ($1.47) to ($1.04). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Inovio Pharmaceuticals.

Inovio Pharmaceuticals (NASDAQ:INO) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.15). Inovio Pharmaceuticals had a negative return on equity of 72.19% and a negative net margin of 221.55%. The company had revenue of $2.60 million during the quarter, compared to analyst estimates of $10.27 million. During the same quarter last year, the business earned ($0.28) earnings per share. The firm’s revenue for the quarter was down 79.2% on a year-over-year basis.

INO has been the topic of several recent research reports. HC Wainwright set a $13.00 price target on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, October 6th. Citigroup initiated coverage on shares of Inovio Pharmaceuticals in a research report on Friday, October 6th. They set a “buy” rating and a $10.00 price target on the stock. Maxim Group set a $12.00 price target on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, January 2nd. Finally, Zacks Investment Research cut shares of Inovio Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the stock. Inovio Pharmaceuticals presently has an average rating of “Hold” and an average target price of $19.16.

Shares of Inovio Pharmaceuticals (INO) traded down $0.08 on Friday, reaching $5.05. 1,544,549 shares of the company’s stock traded hands, compared to its average volume of 1,650,000. Inovio Pharmaceuticals has a 52 week low of $4.09 and a 52 week high of $9.86. The firm has a market cap of $456.00, a PE ratio of -4.28 and a beta of 2.74.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of Montreal Can boosted its holdings in Inovio Pharmaceuticals by 15.5% in the fourth quarter. Bank of Montreal Can now owns 212,108 shares of the biopharmaceutical company’s stock valued at $876,000 after purchasing an additional 28,400 shares in the last quarter. Belpointe Asset Management LLC acquired a new stake in shares of Inovio Pharmaceuticals during the third quarter worth $150,000. Neuberger Berman Group LLC acquired a new stake in shares of Inovio Pharmaceuticals during the third quarter worth $115,000. Alyeska Investment Group L.P. acquired a new stake in shares of Inovio Pharmaceuticals during the third quarter worth $892,000. Finally, Allianz Asset Management GmbH raised its position in shares of Inovio Pharmaceuticals by 12.4% during the third quarter. Allianz Asset Management GmbH now owns 222,768 shares of the biopharmaceutical company’s stock worth $1,412,000 after purchasing an additional 24,652 shares during the period. 32.11% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/28/inovio-pharmaceuticals-inc-ino-expected-to-announce-earnings-of-0-29-per-share.html.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Get a free copy of the Zacks research report on Inovio Pharmaceuticals (INO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply